亚裔美国人食管鳞状细胞癌的特征和临床结果的变化。

IF 1.8 3区医学 Q3 ONCOLOGY

Oncology Pub Date : 2025-02-26 DOI:10.1159/000544841

Xiaoxia Yu, Lixia Xu, Shuwen Zhang, Ping Pan, Ying Xia

{"title":"亚裔美国人食管鳞状细胞癌的特征和临床结果的变化。","authors":"Xiaoxia Yu, Lixia Xu, Shuwen Zhang, Ping Pan, Ying Xia","doi":"10.1159/000544841","DOIUrl":null,"url":null,"abstract":"Introduction: Research on esophageal squamous cell carcinoma (ESCC) in Asian American (AsA) populations frequently aggregates data, thereby overlooking the considerable diversity inherent within this demographic. The aim of this study was to investigate the variations in ESCC characteristics and clinical outcomes among AsA.Methods: Patients diagnosed with ESCC were identified through the Surveillance, Epidemiology, and End Results (SEER) 17 database. The AsA cohort was categorized into specific subgroups: Chinese, Japanese, Filipino, Korean, Vietnamese, South Asian (Asian Indian or Pakistani), and other Asian. The Kaplan-Meier method was employed to estimate unadjusted overall survival (OS), while Cox proportional hazards models were utilized to assess adjusted OS.Results: A total of 9,252 patients were included, with the cohort comprising 1,100 Asian, 2,135 Black, 951 Hispanic, and 5,066 White individuals. AsA patients demonstrated the highest unadjusted OS (p < 0.001). The Vietnamese subgroup exhibited the highest proportion of male patients at 92.1%. South Asian patients showed the highest unadjusted OS among the distinct Asian subgroups, with survival rates of 56% at 1 year (95% confidence interval [CI]: 49-64), 31% at 3 years (95% CI: 25-40), and 23% at 5 years (95% CI: 17-32). After adjusting, only Chinese and South Asian patients displayed significantly improved OS compared to the White reference group (p < 0.05).Conclusion: Considerable disparities in ESCC characteristics and outcomes exist among AsA populations. Socioeconomic, genetic, and epigenetic factors may influence these differences. Further research is essential to clarify the mechanisms of this discrepancy.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-12"},"PeriodicalIF":1.8000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Variations in Characteristics and Clinical Outcomes of Esophageal Squamous Cell Carcinoma among Asian American.\",\"authors\":\"Xiaoxia Yu, Lixia Xu, Shuwen Zhang, Ping Pan, Ying Xia\",\"doi\":\"10.1159/000544841\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Research on esophageal squamous cell carcinoma (ESCC) in Asian American (AsA) populations frequently aggregates data, thereby overlooking the considerable diversity inherent within this demographic. The aim of this study was to investigate the variations in ESCC characteristics and clinical outcomes among AsA.Methods: Patients diagnosed with ESCC were identified through the Surveillance, Epidemiology, and End Results (SEER) 17 database. The AsA cohort was categorized into specific subgroups: Chinese, Japanese, Filipino, Korean, Vietnamese, South Asian (Asian Indian or Pakistani), and other Asian. The Kaplan-Meier method was employed to estimate unadjusted overall survival (OS), while Cox proportional hazards models were utilized to assess adjusted OS.Results: A total of 9,252 patients were included, with the cohort comprising 1,100 Asian, 2,135 Black, 951 Hispanic, and 5,066 White individuals. AsA patients demonstrated the highest unadjusted OS (p < 0.001). The Vietnamese subgroup exhibited the highest proportion of male patients at 92.1%. South Asian patients showed the highest unadjusted OS among the distinct Asian subgroups, with survival rates of 56% at 1 year (95% confidence interval [CI]: 49-64), 31% at 3 years (95% CI: 25-40), and 23% at 5 years (95% CI: 17-32). After adjusting, only Chinese and South Asian patients displayed significantly improved OS compared to the White reference group (p < 0.05).Conclusion: Considerable disparities in ESCC characteristics and outcomes exist among AsA populations. Socioeconomic, genetic, and epigenetic factors may influence these differences. Further research is essential to clarify the mechanisms of this discrepancy.\",\"PeriodicalId\":19497,\"journal\":{\"name\":\"Oncology\",\"volume\":\" \",\"pages\":\"1-12\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-02-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000544841\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000544841","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

亚裔美国人（AsA）人群中食管鳞状细胞癌（ESCC）的研究经常汇总数据，从而忽略了该人群中固有的相当大的多样性。本研究的目的是探讨AsA中ESCC特征和临床结果的变化。方法：通过监测、流行病学和最终结果（SEER） 17数据库确定ESCC患者。AsA队列被分类为特定的亚组：中国人、日本人、菲律宾人、韩国人、越南人、南亚人（亚洲印度人或巴基斯坦人）和其他亚洲人。采用Kaplan-Meier法估计未调整总生存期（OS）， Cox比例风险模型评估调整后的OS。结果：共纳入9252例患者，其中包括1100名亚洲人、2135名黑人、951名西班牙裔和5066名白人。AsA患者未调整OS最高（P < 0.001）。越南亚组男性患者比例最高，为92.1%。南亚患者在不同的亚洲亚组中显示出最高的未调整OS， 1年生存率为56% (95% CI 49-64)， 3年生存率为31% (95% CI 25-40)， 5年生存率为23% （95% CI 17-32）。调整后，与白人参照组相比，只有中国和南亚患者的OS有显著改善（P < 0.05）。结论：AsA人群中ESCC的特征和结局存在相当大的差异。社会经济、遗传和表观遗传因素可能影响这些差异。需要进一步的研究来阐明这种差异的机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Variations in Characteristics and Clinical Outcomes of Esophageal Squamous Cell Carcinoma among Asian American.

Introduction: Research on esophageal squamous cell carcinoma (ESCC) in Asian American (AsA) populations frequently aggregates data, thereby overlooking the considerable diversity inherent within this demographic. The aim of this study was to investigate the variations in ESCC characteristics and clinical outcomes among AsA.

Methods: Patients diagnosed with ESCC were identified through the Surveillance, Epidemiology, and End Results (SEER) 17 database. The AsA cohort was categorized into specific subgroups: Chinese, Japanese, Filipino, Korean, Vietnamese, South Asian (Asian Indian or Pakistani), and other Asian. The Kaplan-Meier method was employed to estimate unadjusted overall survival (OS), while Cox proportional hazards models were utilized to assess adjusted OS.

Results: A total of 9,252 patients were included, with the cohort comprising 1,100 Asian, 2,135 Black, 951 Hispanic, and 5,066 White individuals. AsA patients demonstrated the highest unadjusted OS (p < 0.001). The Vietnamese subgroup exhibited the highest proportion of male patients at 92.1%. South Asian patients showed the highest unadjusted OS among the distinct Asian subgroups, with survival rates of 56% at 1 year (95% confidence interval [CI]: 49-64), 31% at 3 years (95% CI: 25-40), and 23% at 5 years (95% CI: 17-32). After adjusting, only Chinese and South Asian patients displayed significantly improved OS compared to the White reference group (p < 0.05).

Conclusion: Considerable disparities in ESCC characteristics and outcomes exist among AsA populations. Socioeconomic, genetic, and epigenetic factors may influence these differences. Further research is essential to clarify the mechanisms of this discrepancy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.